Form 4: Telomir CEO Erez Aminov Acquires 7.3M Shares in TELI Merger

CEO and Chairman Erez Aminov acquired 7,319,710 shares of Telomir Pharmaceuticals, Inc. common stock as part of the company's acquisition of TELI Pharmaceuticals, Inc.

Summary

• Erez Aminov, CEO and Chairman of Telomir Pharmaceuticals, Inc., acquired 7,319,710 shares of common stock.
• The transaction occurred on April 22, 2026, at a price of $1.37 per share.
• The acquisition was executed as part of the company's strategic acquisition of TELI Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event; while it signals management confidence through increased ownership, the resulting dilution is a standard concern for retail investors.

Positives

• Alignment of interests as the CEO and Chairman increases his direct equity stake in the company.
• Successful completion of the acquisition of TELI Pharmaceuticals, Inc.

Negatives

• The issuance of over 7.3 million shares results in significant dilution for existing shareholders.

Risks

• Integration risks associated with the acquisition of TELI Pharmaceuticals, Inc.
• Potential market volatility following the issuance of a large block of new shares.

Future Outlook

The filing does not provide specific forward-looking financial guidance, focusing instead on the completion of the TELI Pharmaceuticals acquisition.

Management Comments

• The shares were issued in exchange for the Reporting Person's shares of TELI Pharmaceuticals, Inc. in connection with the Issuer's acquisition of TELI.

Industry Context

StockSavvy.ai notes that this transaction reflects a common consolidation strategy in the pharmaceutical sector, where parent companies absorb smaller entities to consolidate intellectual property and pipeline assets.

Comparison to Industry Standards

• The use of stock-for-stock exchanges is a standard mechanism in biotech M&A to preserve cash while aligning management incentives.
• The valuation of $1.37 per share is consistent with typical small-cap biotech equity issuance structures.

Related Party Transactions

• The transaction involves the CEO and Chairman, Erez Aminov, acquiring shares in exchange for his holdings in the acquired entity, TELI Pharmaceuticals.

Stakeholder Impact

• Existing shareholders face dilution due to the issuance of 7.3 million new shares.
• The acquisition may provide long-term value through the consolidation of pharmaceutical assets.

Next Steps

• Integration of TELI Pharmaceuticals operations into Telomir Pharmaceuticals.

Key Dates

Recommendation

The acquisition is a strategic move that warrants a hold recommendation until the market assesses the value of the newly acquired assets against the dilution impact.

Keywords

Telomir Pharmaceuticals, TELO, Erez Aminov, Insider Transaction, Merger and Acquisition, Form 4